The patents received from canada, ARIPO and South Korea are valid through 2030
Suven Life Sciences has received grant of one product patent from Canada (2823548), one product patent from African Regional Intellectual Property Organization (ARIPO) (AP 3307) and one product patent from South Korea (10-1551481) ) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases and these patents are valid through 2030.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of 21 granted patents from Canada, two granted product patents from ARIPO and 19 granted patents from South Korea. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
- Advertisement -
Comments are closed.